News
Two med-tech companies focused on pulmonary embolism overcame their own blockages to commercialization this week. Inquis ...
With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback